Horizon Pharma PLC Company Profile (NASDAQ:HZNP)

Horizon Pharma PLC trades on the NASDAQ under the ticker symbol "HZNP."

Horizon Pharma PLC declared that its Board of Directors has authorized a stock buyback plan on Sunday, June 4th 2017, which allows the company to repurchase 1,000% of outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company's board believes its shares are undervalued.

Horizon Pharma PLC (NASDAQ:HZNP) posted its quarterly earnings results on Monday, May, 8th. The company reported $0.21 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.25 by $0.04. The business earned $220.90 million during the quarter, compared to analysts' expectations of $248.71 million. Horizon Pharma PLC had a positive return on equity of 21.51% and a negative net margin of 21.26%. The firm's quarterly revenue was up 7.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.34 earnings per share. View Horizon Pharma PLC's Earnings History.

12 equities research analysts have issued 12-month price targets for Horizon Pharma PLC's stock. Their forecasts range from $10.00 to $32.00. On average, they expect Horizon Pharma PLC's share price to reach $20.42 in the next year. View Analyst Ratings for Horizon Pharma PLC.

Here are some recent quotes from research analysts about Horizon Pharma PLC stock:

• 1. According to Zacks Investment Research, "Horizon’s results from the primary care business units was much below expectations in the first quarter due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. The company plans to overcome this underperformance by reducing certain costs in the primary care business unit in order to align its cost structure with the lower- than-expected sales. Due to the divestiture of Procysbi, the company now expects sales in 2017 to come around $985 million to $1.020 billion. On a positive note, Horizon is significantly increasing investments in one its key drugs, Krystexxa. Shares of the company have underperformed the Zacks classified industry." (7/11/2017)
• 2. Piper Jaffray Companies analysts commented, "We had the opportunity to travel with Horizon senior management in meetings with investors. We gained additional insight into Pennsaid 2% and Ravicti, and also came away with insights into management's latest thinking regarding M&A. Though there are undoubtedly some headwinds facing the primary care segment, we believe that this segment should be on largely stable footing over the long-term given HZNP's payer contracting efforts. That dynamic combined with continued strength from the rare disease segment points to a long-term EPS CAGR (2017-2022) in the mid-teens, and should translate into multiple expansion with a 2017E P/E currently at 7x. We reiterate our Overweight rating and are lowering our PT to $30 from $32 (see below for more details)." (3/24/2017)
• 3. Guggenheim analysts commented, "HZNP reported a 4Q16 beat, underscoring our confidence that HZNP can continue to meet or exceed earnings expectations in '17+. Post 4Q16, we think that the peak sales potential of Pennsaid 2%, Procysbi, and Krystexxa are underappreciated, with additional earnings upside potentially coming from M&A as HZNP redeploys cash generated by its Primary Care ("PC") business into business development focused on orphan and rare disease indication medicines. While concerns remain over growth prospects for HZNP's PC business, Ravicti and Actimmune, these assets continue to generate meaningful cash to fuel HZNP's growth aspiration of $2B in sales by 2020." (2/27/2017)
• 4. Mizuho analysts commented, "We are positive on HZNP ahead of the February 27 earnings call: We think the company may deliver a 4Q:16 earnings beat. We model 4Q:16 revenues of $325.4M and EPS of $0.57 relative to consensus $308.5M and $0.50 and implied guidance $309-$314M. Horizon has delivered strong beats in the past and we expect adjusted EBITDA to approach the higher end of the guidance range of $450-$460M. With respect to 2017 guidance, we fall below FactSet consensus estimates of $1,289.7M and $2.39 (we model $1,281.8M and $2.29), but note that Horizon may be able to beat this range via a combination of both price and volume growth, so guidance could come in stronger than expected. There is still significant uncertainty around business operation under the new PBM contracts, gross to net discounts, infrastructure needs, and the timing of anticipated volume growth. We therefore expect the focus of the call to be around these issues as well as on future business development targets and pipeline outlook." (2/22/2017)

Horizon Pharma PLC saw a increase in short interest in July. As of July 14th, there was short interest totalling 17,983,730 shares, an increase of 18.7% from the June 30th total of 15,145,389 shares. Based on an average trading volume of 3,072,098 shares, the short-interest ratio is presently 5.9 days. Approximately 11.2% of the company's shares are sold short.

Some companies that are related to Horizon Pharma PLC include Akorn (AKRX), Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Amicus Therapeutics (FOLD), Cambrex Corporation (CBM), Theravance Biopharma (TBPH), Pacira Pharmaceuticals (PCRX), Innoviva (INVA), Impax Laboratories (IPXL), Corcept Therapeutics Incorporated (CORT), Amphastar Pharmaceuticals (AMPH), Lannett Co (LCI), AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN), Aceto Corporation (ACET), Teligent (TLGT) and Collegium Pharmaceutical (COLL).

Horizon Pharma PLC's management team includes the folowing people:

• Timothy P. Walbert, Chairman of the Board, President, Chief Executive Officer
• Paul W. Hoelscher, Chief Financial Officer, Executive Vice President
• Brian K. Beeler, Executive Vice President, General Counsel
• David G. Kelly, Executive Vice President, Company Secretary and Managing Director, Ireland
• John B. Thomas, Executive Vice President, Strategy and Investor Relations
• Robert F. Carey, Executive Vice President, Chief Business Officer
• George P. Hampton, Executive Vice President - Orphan and Primary Care Business Units and International Operations
• Jeffrey W. Sherman M.D., Executive Vice President - Research and Development and Chief Medical Officer
• Timothy J. Ackerman, Senior Vice President - Commercial Operations
• Geoffrey M. Curtis, Senior Vice President - Corporate Communications

Horizon Pharma PLC's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Deltec Asset Management LLC (0.15%), Russell Investments Group Ltd. (0.09%), American National Insurance Co. TX (0.09%), Parkwood LLC (0.06%), US Bancorp DE (0.05%) and Creative Planning (0.04%). Company insiders that own Horizon Pharma PLC stock include Jeffrey W Sherman, Michael G Grey, Robert Carey and Virinder Nohria. View Institutional Ownership Trends for Horizon Pharma PLC.

Horizon Pharma PLC's stock was sold by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have sold Horizon Pharma PLC stock in the last year include Jeffrey W Sherman and Robert Carey. View Insider Buying and Selling for Horizon Pharma PLC.

Horizon Pharma PLC's stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Malaga Cove Capital LLC, US Bancorp DE, Deltec Asset Management LLC, Fox Run Management L.L.C. and Bank of Montreal Can. View Insider Buying and Selling for Horizon Pharma PLC.

Shares of Horizon Pharma PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Horizon Pharma PLC stock can currently be purchased for approximately $13.22.